Pioglitazone which has been used to overcome insulin resistance in diabetic patients may prove to be an alternative supportive treatment to overcome the weight loss due to cancer, particularly in patients with lymphatic cancer non-Hodgkin's lymphoma (non-Hodgkin's lymphoma malignum). This condition can be considered as a serious malnutrition. Malnutrition is the condition that occurs when your body does not get enough nutrients. Pioglitazone may improve nutritional status, and insulin resistance.
What is Pioglitazone?
Pioglitazone is an Antidiabetic used for Diabetes mellitus (type 2). It is also called as Actos® Competact® (a combination of pioglitazone and metformin). Available as
Tablets. Pioglitazone works by helping your body make better use of the insulin it produces.
Nutritional disorders frequently occur in cancer patients, before or during treatment, as well as in advanced cancer. This is so the cause of increased morbidity and mortality.
An increase in body mass index above 2 kilograms per square meter in the group of patients who received pioglitazone after the 4 cycles of therapy as much as 33.3 percent of patients. As for which no cure is only 12.5 percent.
The use of pioglitazone at a dose of 30 μ gram per day to 12 weeks is safe, no side effects found in the form of hypoglycemia, impaired renal function, significant liver function in patients.
No comments:
Post a Comment